Physician profile
Molly Pulchtopek
NPI 1942819685
$3,440.27
in general payments reported to CMS, 2019-2025
24 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $336 · 2022: $1,217 · 2023: $1,367 · 2024: $260 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $527.73 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $360.28 | 2021-2025 | Camzyos, Eliquis |
| Amgen INC. | $342.27 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $342.00 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $289.50 | 2021-2023 | Verquvo, Belsomra |
| Harmony Biosciences LLC | $246.21 | 2022-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.63 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $169.04 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $141.45 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Astrazeneca Pharmaceuticals Lp | $141.42 | 2021-2024 | Airsupra |
| Novo Nordisk INC | $123.68 | 2023-2024 | Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals, Ltd. | $122.02 | 2022-2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $64.82 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.89 | 2021-2022 | |
| Heartflow, INC. | $61.81 | 2022-2023 | Ffrct |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $49.66 | 2022-2025 | Nucala |
| Scpharmaceuticals INC. | $48.23 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $39.13 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.14 | 2024 | Glassia |
| Avadel Cns Pharmaceuticals, LLC | $19.64 | 2023 | Lumryz |
| Impulse Dynamics (USA) INC. | $17.08 | 2023 | Optimizer |
| Esperion Therapeutics, INC. | $14.39 | 2024 | Nexletol |
| Amarin Pharma, INC. | $12.24 | 2021 | |
| Altathera Pharmaceuticals LLC | $10.01 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Pulchtopek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.